These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32945500)

  • 1. Inactivation of AKT/NF‑κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin.
    Dukaew N; Chairatvit K; Pitchakarn P; Imsumran A; Karinchai J; Tuntiwechapikul W; Wongnoppavich A
    Oncol Rep; 2020 Oct; 44(4):1441-1454. PubMed ID: 32945500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Radiosensitivity by Eurycomalactone in Human NSCLC Cells Through G₂/M Cell Cycle Arrest and Delayed DNA Double-Strand Break Repair.
    Dukaew N; Konishi T; Chairatvit K; Autsavapromporn N; Soonthornchareonnon N; Wongnoppavich A
    Oncol Res; 2020 Mar; 28(2):161-175. PubMed ID: 31727206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione Peroxidase 1 Promotes NSCLC Resistance to Cisplatin via ROS-Induced Activation of PI3K/AKT Pathway.
    Chen B; Shen Z; Wu D; Xie X; Xu X; Lv L; Dai H; Chen J; Gan X
    Biomed Res Int; 2019; 2019():7640547. PubMed ID: 31032363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell.
    Fayi MA; Alamri A; Rajagopalan P
    Oncol Res; 2020 Mar; 28(2):177-189. PubMed ID: 31771696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
    Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
    Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis.
    Zhao X; Xu Z; Wang Z; Wu Z; Gong Y; Zhou L; Xiang Y
    Mol Med Rep; 2015 Jul; 12(1):960-6. PubMed ID: 25760437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
    Liu J; Xing Y; Rong L
    Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetyl-11-keto-β-boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway.
    Lv M; Zhuang X; Zhang Q; Cheng Y; Wu D; Wang X; Qiao T
    Cell Biol Toxicol; 2021 Apr; 37(2):209-228. PubMed ID: 32562082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway.
    Chen TJ; Zhou YF; Ning JJ; Yang T; Ren H; Li Y; Zhang S; Chen MW
    Cell Physiol Biochem; 2015; 36(3):893-906. PubMed ID: 26065336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
    Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
    Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.